BA, Cornell University (2006)
CJ PARTNERS Inc., Managing Director (2012-Present)
SMBC Nikko Securities Inc., Manager (2010-2012)
Deloitte Tohmatsu Consulting, Senior Consultant (2007-2010)
Cell Therapies, Gene Therapies, Tissue Engineering, Japanese Regulatory Environment, cell/gene therapy manufacturing, cell/gene therapy clinical development, regenerative medicine market analysis, etc.
Honors & Awards
Class-1 Sales Representative from the Japan Securities Dealers Association (2012)
1). How Japan Is Creating New Opportunities in the Field of Regenerative Medicine, 26 FEB 2018, Harvard Business Review (Interviewed as part of piece)
2). Companies Flocking to Japan for Biotech Deals, 01 FEB 2017, The Life Sciences Report (Spotlight Interview piece)
3). Japan's regulatory gamble and what it means for the Industry, 16 SEP 2015, Cell & Gene Therapy Insights (authored in collaboration with Lee Buckler)
Regenerative Medicine in Japan
The presentation will provide an in-depth overview of regenerative medicine in Japan covering such topics as the country's regenerative medicine regulatory environment, regulatory consultations, national health insurance drug pricing for regenerative medicine products, the overall regenerative medicine market. In particular, the regulatory environment section will look to provide the audience with more clarity on the differences between the two laws regulating regenerative medicine products in Japan (i.e. the PMD. Act & the ASRM), while the regenerative medicine market section will look to provide similar clarity on the types of support that the industry receives from various market sectors, the large number of Japanese pharmaceutical companies involved in the sector, the large number of cross border deals that have been struck between Japanese and non-Japanese entities, alongside some insights into the types of regenerative medicine clinical trials that are currently underway on the Japanese archipelago. The presentation will look to allow audience members to more fully understand "what all the fuss is about" when it comes to regenerative medicine in Japan, and come to a better appreciation of what is at stake should one choose not to focus on what is occurring there.